Product Dossier
LECTEVA
Product Dossier for LECTEVA (carbidopa, entacapone, levodopa, Teva Pharma). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Teva Pharma
- Active ingredient: carbidopa, entacapone, levodopa
- Therapeutic area: Neurology
- Related brand: SINEMET
- Related brand: COMTAN
- Related brand: SINADOPA
- Same area: GILENYA
- Same area: RIVOTRIL
What it is
LECTEVA is a combination medicine containing levodopa, carbidopa and entacapone. The tablet strengths available are 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg, 150 mg/37.5 mg/200 mg, 175 mg/43.75 mg/200 mg, and 200 mg/50 mg/200 mg.
Approved indications
The provided source documents do not contain information about the approved indications for LECTEVA.
Dosing overview
The provided source documents do not contain dosing information specific to LECTEVA.
Key safety warnings
The provided source documents do not contain safety warning information specific to LECTEVA.
Contraindications
The provided source documents do not contain contraindication information specific to LECTEVA.
PBS listing
The provided source documents do not contain PBS listing information for LECTEVA.
Regulatory history
LECTEVA was first registered on the Australian Register of Therapeutic Goods on 7 April 2016, with seven tablet strengths registered concurrently.